PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic’s composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of...
PRESS RELEASE – PRIVILEGED INFORMATION The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of...
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in...
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious...
PRESS RELEASE – REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET –...
PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023. BioSenic has prepared a global restructuring plan covering the years...
PRESS RELEASE “ REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST “ BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...
Mont-Saint-Guibert, Belgium, 27 May 2024, 5:00pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy announces today that it has obtained a positive vote of its creditors on its restructuration Plan within the request referred to in Article XX 83/26 ELC within the Enterprise Court of Nivelles. The Plan provides for differentiated treatment of creditors by class. Creditors have been asked to express their vote on the said Plan in front of the Court, with the following main points:
PRESS RELEASE “ REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET “ BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious...